Rule 3.19A.2

# **Appendix 3Y**

### **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Regis Healthcare Ltd
ABN	11 125 203 054

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Linda Jane Mellors
Date of last notice	26 September 2024

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Performance Rights granted to Dr Mellors by the Company pursuant to the FY24 STI Plan. Upon vesting, each Right may be exercised and exchanged for one fully paid Ordinary Share in the capital of the Company. The Board retains a discretion to make a cash equivalent payment instead of allocation of Ordinary Shares.  Cessation of Performance Rights under FY23 STI Plan pursuant to exercise of Board discretion to make a cash equivalent payment instead of allocation of Ordinary Shares.	
Date of change	27 September 2024	
No. of securities held prior to change	284,270 Ordinary Shares 798,104 Rights (unquoted)	
Class	Rights (unquoted)	
Number acquired	18,163 Rights (unquoted) pursuant to FY24 STI Plan.	

<sup>+</sup> See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Number disposed	39,889 Rights (unquoted) pursuant to FY23 STI Plan.
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	No cash consideration in respect of FY24 STI Rights issued. No amount is payable on vesting of Rights or exchange for Ordinary Shares. The Company will procure the number of Ordinary Shares in respect of vested Rights on-market. The Board retains a discretion to make a cash equivalent payment instead of allocation of Ordinary Shares.
	Cash consideration of \$245,565 paid in respect of FY23 STI Rights cancelled. Cash amount equivalent to market value based on the 5 trading day volume weighted average price for the period 23 to 27 September 2024.
No. of securities held after change	284,270 Ordinary Shares 776,378 Rights (unquoted)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Issue of Performance rights under FY24 STI Plan (subject to a continued employment condition).
	Cessation of performance rights under FY23 STI Plan pursuant to payment of cash instead of share issue or purchase.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the	N/A
trade to proceed during this period?	
If prior written clearance was provided, on what date was	N/A
this provided?	

01/01/2011 Appendix 3Y Page 3

<sup>+</sup> See chapter 19 for defined terms.